We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered ... Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Show more
The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash...
MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.09 | -19.619047619 | 15.75 | 16.14 | 5.03 | 404536 | 15.17122328 | CS |
4 | -2.91 | -18.6897880539 | 15.57 | 16.5431 | 5.03 | 218897 | 15.49387289 | CS |
12 | -4.29 | -25.3097345133 | 16.95 | 18 | 5.03 | 269178 | 15.39310274 | CS |
26 | -4.23 | -25.0444049734 | 16.89 | 19.77 | 5.03 | 312809 | 16.19114207 | CS |
52 | 0.66 | 5.5 | 12 | 22.188 | 5.03 | 254311 | 16.34720117 | CS |
156 | -4.74 | -27.2413793103 | 17.4 | 22.188 | 4.81 | 125930 | 14.22329141 | CS |
260 | -0.58 | -4.38066465257 | 13.24 | 33.01 | 4.03 | 107244 | 16.32290712 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions